Provided by Tiger Trade Technology Pte. Ltd.

ZYMEWORKS INC (US)

27.48
+1.244.73%
Post-market: 27.510.0306+0.11%16:11 EDT
Volume:979.84K
Turnover:26.94M
Market Cap:1.95B
PE:-13.60
High:27.86
Open:27.15
Low:26.72
Close:26.24
52wk High:31.34
52wk Low:15.79
Shares:70.96M
Float Shares:66.05M
Volume Ratio:1.37
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0200
EPS(LYR):-1.0800
ROE:-72.31%
ROA:-24.14%
PB:24.26
PE(LYR):-25.44

Loading ...

Zymeworks Initiated at Outperform by Wolfe Research

Dow Jones
·
Yesterday

Zymeworks initiated with an Outperform at Wolfe Research

TIPRANKS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)

TIPRANKS
·
Sep 10

Theravance Biopharma Announces Shareholder Meeting on Merger Deal

Reuters
·
Sep 10

Zymeworks (ZYME) Secures FDA Approval And $250 Million Milestone, Is The Stock Still Undervalued?

Simply Wall St.
·
Aug 27

Zymeworks price target raised to $38 from $37 at Citi

TIPRANKS
·
Aug 26

Zymeworks Price Target Raised to $55.00/Share from $51.00 by HC Wainwright & Co.

Dow Jones
·
Aug 26

Zymeworks price target raised to $55 from $51 at H.C. Wainwright

TIPRANKS
·
Aug 26

Analysts Are Bullish on These Healthcare Stocks: Zymeworks (ZYME), Johnson & Johnson (JNJ)

TIPRANKS
·
Aug 26

Jazz Wins FDA Approval for Ziihera Regimens in First-Line HER2+ Gastroesophageal Cancer, Triggering USD 250 Million Zymeworks Milestone

Reuters
·
Aug 25

U.S. FDA Approves Ziihera® (Zanidatamab-Hrii) with and Without Tislelizumab Plus Chemotherapy in First-Line Her2+ Advanced Gastroesophageal Adenocarcinoma

THOMSON REUTERS
·
Aug 25

Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)

TIPRANKS
·
Aug 13

Zymeworks Management Attends Wells Fargo Healthcare Conference Fireside Chat

Reuters
·
Aug 11

Zymeworks Price Target Raised to $44.00/Share from $40.00 by B. Riley Securities

Dow Jones
·
Aug 11

Ireland's Theravance Biopharma Q2 Revenue Rises 11% but Misses Estimates

Reuters
·
Aug 10

B. Riley Adjusts Zymeworks Price Target to $44 From $40, Maintains Buy Rating

MT Newswires Live
·
Aug 10

Zymeworks price target raised to $32 from $31 at Truist

TIPRANKS
·
Aug 07

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 07

Zymeworks Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Zymeworks Revenue Drops 90.57% to $4.6 Million in FY26 Q2; Net Loss Widens to $45 Million

Reuters
·
Aug 07